Efforts to develop unbiased screens for identifying novel functionblocking monoclonal antibodies (mAbs) in human carcinomatous states have been hampered by the limited ability to design in vitro models that recapitulate tumor cell behavior in vivo. Given that only invasive carcinoma cells gain permanent access to type I collagen-rich interstitial tissues, an experimental platform was established in which human breast cancer cells were embedded in 3D aldimine cross-linked collagen matrices and used as an immunogen to generate mAb libraries. In turn, cancer-cell-reactive antibodies were screened for their ability to block carcinoma cell proliferation within collagen hydrogels that mimic the in vivo environment. As a proof of principle, a single function-blocking mAb out of 15 identified was selected for further analysis and found to be capable of halting carcinoma cell proliferation, inducing apoptosis, and exerting global changes in gene expression in vitro. The ability of this mAb to block carcinoma cell proliferation and metastatic activity was confirmed in vivo, and the target antigen was identified by mass spectroscopy as the α 2 subunit of the α 2 β 1 integrin, one of the major type I collagen-binding receptors in mammalian cells. Validating the ability of the in vitro model to predict patterns of antigen expression in the disease setting, immunohistochemical analyses of tissues from patients with breast cancer verified markedly increased expression of the α 2 subunit in vivo. These results not only highlight the utility of this discovery platform for rapidly selecting and characterizing function-blocking, anticancer mAbs in an unbiased fashion, but also identify α 2 β 1 as a potential target in human carcinomatous states. extracellular matrix | metastasis | bone | MDA-MB-231 | mouse model I n mammalian systems, a specialized form of extracellular matrix (ECM), termed the basement membrane, normally separates epithelial cells from the underlying type I collagen-rich interstitial matrix (1, 2). Thus, in mature animals and under physiologic conditions, the epithelium does not establish stable physical contacts with interstitial tissues (1, 2). In contrast, in neoplastic states, transformed epithelial cells (i.e., carcinomas) dissolve the intervening basement membrane barrier and establish adhesive interactions with the newly exposed type I collagen fibrillar network (1-5). As carcinoma cells begin to infiltrate the interstitial matrix, they rapidly adapt themselves to their 3D environment and initiate the proliferative phenotypes that define tumor progression at both primary and metastatic sites (2, 6, 7). Indeed, emphasizing the importance of the tumor-ECM interface, carcinoma cells do not simply use the surrounding interstitial matrix as a passive substrate, but actively promote increased type I collagen deposition within the peritumoral microenvironment as a means of further enhancing invasive activity, local growth, and cancer stem cell formation (7)(8) (9) (10) (11) (12) .
Efforts to develop unbiased screens for identifying novel functionblocking monoclonal antibodies (mAbs) in human carcinomatous states have been hampered by the limited ability to design in vitro models that recapitulate tumor cell behavior in vivo. Given that only invasive carcinoma cells gain permanent access to type I collagen-rich interstitial tissues, an experimental platform was established in which human breast cancer cells were embedded in 3D aldimine cross-linked collagen matrices and used as an immunogen to generate mAb libraries. In turn, cancer-cell-reactive antibodies were screened for their ability to block carcinoma cell proliferation within collagen hydrogels that mimic the in vivo environment. As a proof of principle, a single function-blocking mAb out of 15 identified was selected for further analysis and found to be capable of halting carcinoma cell proliferation, inducing apoptosis, and exerting global changes in gene expression in vitro. The ability of this mAb to block carcinoma cell proliferation and metastatic activity was confirmed in vivo, and the target antigen was identified by mass spectroscopy as the α 2 subunit of the α 2 β 1 integrin, one of the major type I collagen-binding receptors in mammalian cells. Validating the ability of the in vitro model to predict patterns of antigen expression in the disease setting, immunohistochemical analyses of tissues from patients with breast cancer verified markedly increased expression of the α 2 subunit in vivo. These results not only highlight the utility of this discovery platform for rapidly selecting and characterizing function-blocking, anticancer mAbs in an unbiased fashion, but also identify α 2 β 1 as a potential target in human carcinomatous states. extracellular matrix | metastasis | bone | MDA-MB-231 | mouse model I n mammalian systems, a specialized form of extracellular matrix (ECM), termed the basement membrane, normally separates epithelial cells from the underlying type I collagen-rich interstitial matrix (1, 2) . Thus, in mature animals and under physiologic conditions, the epithelium does not establish stable physical contacts with interstitial tissues (1, 2) . In contrast, in neoplastic states, transformed epithelial cells (i.e., carcinomas) dissolve the intervening basement membrane barrier and establish adhesive interactions with the newly exposed type I collagen fibrillar network (1) (2) (3) (4) (5) . As carcinoma cells begin to infiltrate the interstitial matrix, they rapidly adapt themselves to their 3D environment and initiate the proliferative phenotypes that define tumor progression at both primary and metastatic sites (2, 6, 7) . Indeed, emphasizing the importance of the tumor-ECM interface, carcinoma cells do not simply use the surrounding interstitial matrix as a passive substrate, but actively promote increased type I collagen deposition within the peritumoral microenvironment as a means of further enhancing invasive activity, local growth, and cancer stem cell formation (7) (8) (9) (10) (11) (12) .
Despite the importance of the carcinoma cell-type I collagen interface in vivo, therapeutic interventions that directly interfere with the specific cell-ECM interactions operating within this specialized tumor milieu have yet to be identified. Traditionally, new therapeutic agents are developed by identifying a preferred candidate and then generating a specific inhibitor for a targeted effector (13) . In this regard, humanized monoclonal antibodies (mAbs) have been established as important players in the therapeutic armamentarium (13, 14) . Strategies that allow for the rapid identification and validation of new targets remain problematic, however (13) .
Cogent arguments have been forwarded regarding the utility of phenotypic screens for the purpose of identifying new targets in an unbiased fashion (13, 15) . Nevertheless, leveraging this approach requires the engineering of in vitro conditions that faithfully recapitulate carcinoma cell behavior in vivo, so that targets can be identified and their functional contribution assessed rapidly before in vivo testing. To this end, here we describe a novel screening platform wherein human carcinoma cells are cultured within aldimine cross-linked, 3D type I collagen hydrogels similar to those found at invasive sites in vivo (16) , and the cancer cell-matrix composite used to generate a library of mAbs. In turn, the mAbs are then screened for their ability to suppress carcinoma cell proliferative responses under 3D growth conditions. Validating the utility of our in vitro approach, selected mAbs are shown to inhibit carcinoma cell proliferation and metastatic activity in xenograft models in vivo. Finally, using a combination of immunopurification, mass spectroscopy, and peptide mapping, the target antigens can be identified and their expression confirmed in human cancer tissues. Taken together, these findings not only establish a platform that allows for the
Significance
To select for novel monoclonal antibodies (mAbs) with anticancer activity, an experimental platform was established wherein human breast cancer cells were embedded in 3D collagen matrices and used as an immunogen to generate mAb libraries. Fifteen mAbs capable of inhibiting carcinoma cell growth in vitro were generated. A single function-blocking mAb was selected for further analysis and then validated as a potent inhibitor of carcinoma cell behavior in vivo. The target antigen was identified as the α 2 subunit of the α 2 β 1 integrin, a major type I collagen-binding receptor whose expression was confirmed in tissues of patients with breast cancer. These findings describe a new discovery platform that allows for the rapid selection of function-blocking antibodies and identify α 2 β 1 as a potential target in carcinomatous states. rapid identification of function-blocking mAbs and their targets, but also provide key insights into regulation of the carcinoma cell-ECM interface within the in vivo setting.
Results
Characterization of Function-Blocking mAbs Directed Against MDA-MB-231 Carcinoma Cells. MDA-MB-231 cells are a well-characterized, triple-negative breast carcinoma cell line whose gene expression profile closely recapitulates that found in human breast cancer tissues (17) (18) (19) . Furthermore, in a manner similar to human carcinomas expanding in vivo, the cell line undergoes rapid proliferative and tissue-invasive responses when cultured within 3D type I collagen hydrogels in vitro (16, 20, 21) . As such, MDA-MB-231 cells were embedded in covalently cross-linked networks of mouse type I collagen with an elastic modulus similar to that found in normal breast tissue, ∼150 Pa (11). After a 3-d culture period, the human carcinoma cell-mouse matrix composite was then recovered and used as an immunogen to generate a panel of ∼2,500 mAbs (Fig. S1 ). To identify MDA-MB-231-reactive clones, whole-cell-based ELISAs were then performed with ∼350 of the mAbs that scored positive in initial screens. Each of the reactive clones was then expanded, and the individual mAbs were tested for their ability to inhibit the proliferative responses of MDA-MB-231 cells in 3D culture (Fig. S1 ).
When embedded in 3D type I collagen hydrogels, MDA-MB-231 cells rapidly changed their morphology from a spherical to a bipolar, mesenchymal cell-like phenotype over the first 48 h before the initiation of proliferative responses ( Fig. 1 A and B) . Among the 15 mAbs displaying inhibitory activity in our initial screens, clone 4C3 was one of the most potent IgG1 class antibodies identified, displaying an ability to almost completely block MDA-MB-231 cell shape changes and proliferation in 3D collagen ( Fig. 1 A and B) . Moreover, inhibitory activity was not limited to a "preventative" protocol wherein mAb 4C3 was added at the start of the 3D culture period; addition of the inhibitory mAb at 4 d after the start of the culture period similarly inhibited carcinoma cell proliferation, with an IC 50 of ∼0.05 μg/mL ( Fig. 1 B  and C) . Furthermore, 4C3 not only blocked MDA-MB-231 proliferative responses, but also initiated apoptosis in 3D culture as assessed by caspase 3 and 7 activation (Fig. 1D) . In contrast, when cultured under standard 2D conditions atop tissue culturetreated plastic substrata or within 3D Matrigel, an ECM extract that neither recapitulates the structure of normal basement membranes structure nor that of the interstitial matrix (1, 2), mAb 4C3 exerted no inhibitory effects on MDA-MB-231 cell function (Fig. S2) . Interestingly, the antiproliferative activity of mAb 4C3 is not confined to MDA-MB-231 carcinoma cells; similar inhibitory effects can be observed with human squamous cell carcinoma, ovarian carcinoma, and fibrosarcoma cell lines in 3D culture (Fig. S3) .
mAb 4C3 Exerts Global Effects on the MDA-MB-231 Transcriptome. In an effort to identify the potential signaling networks impacted by mAb 4C3, we cultured MDA-MB-231 cells in 3D type I collagen hydrogels in the presence of either a control IgG1 or mAb 4C3 for 48 h (i.e., before the initiation of proliferative responses), and RNA was harvested for gene expression profiling. Under these conditions, mAb 4C3 exerted global effects on gene expression, with almost 1,200 unique transcripts affected (i.e., 172 up-regulated and 1,004 down-regulated transcripts, respectively, using a 2.0-fold cutoff). Consistent with its effect on MDA-MB-231 proliferation, Gene Ontology analysis revealed that mAb 4C3 treatment elicited major alterations in cell cycle, regulation, RNA processing, and cell division-related programs ( Fig. 1 E  and F) . Taken together, these results identify mAb 4C3 as a potent regulator of MDA-MB-231 cell function within the confines of a type I collagen-rich ECM. mAb 4C3 Prevents Postextravasation Carcinoma Growth In Vivo. In our in vitro model, embedded carcinoma cells are individually surrounded by a network of type I collagen fibrils, a scenario similar to that encountered when circulating tumor cells extravasate from vascular or lymphatic beds and enmesh themselves within the perivascular interstitial matrix (1-3, 6, 12) . To examine the inhibitory potential of mAb 4C3 in a postextravasation program directly, we used a live embryonic chick xenograft model that faithfully recapitulates carcinoma cell behavior in mouse models (22, 23) . As shown in Fig. 2A , the chick chorioallantoic membrane vasculature is readily visualized by confocal laser microscopy. Furthermore, using second harmonic generation to image type I collagen fibrils in situ (24) revealed that blood vessels were uniformly invested by a dense collagenous network (Fig. 2B ).
As such, fluorescent-tagged MDA-MB-231 cells were injected into the host vasculature of 11-d-old immuno-incompetent chicken embryos in tandem with a control IgG1 or mAb 4C3, and postextravasation growth was monitored. After a 6-d culture period in vivo, extravasated MDA-MB-231 cells initiated proliferative activity in close association with the chick vasculature (Fig. 2C ). In contrast, in the presence of mAb 4C3, MDA-MB-231 cell proliferation was markedly inhibited, where tumor colony formation was readily monitored by both visual inspection and quantification of luminescent signals using luciferase-tagged carcinoma cells (Fig. 2 C-F) .
To rule out the possibility that 4C3 blocks proliferative responses by interfering with MDA-MB-231 extravasation itself, we injected carcinoma cells into the chick vasculature, and after a 24-h period that allows for the completion of extravasation (23), introduced mAb 4C3 intravascularly. Even under these conditions, mAb 4C3 exerted potent inhibitory effects, equivalent to those obtained when the antibody was introduced at the start of the in vivo assay (Fig. 2F ).
Antimetastatic Activity of mAb 4C3 in a Mouse Xenograft Model.
Unlike humans, whose mammary tissues are dominated by type I collagen, the mouse mammary gland contains only small amounts of type I collagen that is largely confined to periductal regions, thus rendering mouse xenograft orthotopic models less useful for analyzing carcinoma cell-type I collagen matrix interactions (25) . Alternatively, the organic matrix of mouse bone, like that of humans, is composed largely of type I collagen (17, (26) (27) (28) . Furthermore, bone is a frequent site of breast cancer metastatic activity in human disease (17) . As such, after intracardiac injection, we assessed the ability of luciferasetagged MDA-MB-231 to generate bone metastatic lesions in nude mouse recipients in the presence of control IgG1 or mAb 4C3 by in vivo imaging as well as micro-CT analyses over a 28-d assay period.
When treated with twice-weekly dosages of 10 mg/kg of the control mAb, MDA-MB-231 cells generated large tumors in the mandible, hindlimb, and spine of inoculated mice ( Fig. 3 A and  B) . In contrast, in the mAb 4C3-treated group, carcinoma growth in the mandible and hindlimb was impaired, with significant inhibitory effects recorded in vertebral metastases where boneerosive lesions were readily observed in micro-CT scans of the control antibody-treated group (Fig. 3 A-C) . Whereas ∼50% of the control antibody-treated mice required euthanization due to spinal cord compression and resulting limb paralysis, fewer than 20% of the mAb 4C3-treated mice were similarly affected, consistent with the ability of mAb 4C3 to block the progression of bony metastases (Fig. 3D) .
Identification of the mAb 4C3 Target Antigen and Its Expression in
Human Breast Cancer Bone Metastases. To identify the target antigen recognized by mAb 4C3, we applied whole-cell lysates of MDA-MB-231 cells to immunoaffinity columns constructed using the purified antibody as the capturing agent. After antigen recovery, a major bond of ∼150 kDa was isolated and submitted for mass spectrometry analysis after trypsin fragmentation (Fig.  4A ). Bioinformatic analysis of the generated fragments identified the target antigen as the integrin subunit, alpha 2 (α 2 ) (29, 30). Immunoprecipitation of MDA-MB-231 lysates with mAb 4C3, followed by immunoblotting with an independent anti-α 2 antibody, further confirmed the target antigen as the α 2 integrin subunit (Fig. 4B) .
Consistent with the fact that α 2 integrin subunit only forms heterodimeric complexes with the β1 integrin to generate the dominant mammalian type I collagen receptor, α 2 β 1 peptide mapping of mAb 4C3 interactions with the α 2 subunit identified a major epitope lying within the α-I domain of the integrin, the dominant type I collagen recognition site of the α 2 β 1 heterodimer (29, 30) (Fig. 4C) . As expected from its collagen-binding properties, mAb 4C3 inhibited MDA-MB-231 adhesive interactions with type I collagen (Fig. 1C) . Interestingly, a second, inhibitory α 2 integrin-reactive mAb that was identified independently in our screen (mAb 8F10) also bound to a distinct, but overlapping, epitope located within the α-I domain (Fig. S4) .
Given these results, along with earlier studies demonstrating the ability of MDA-MB-231 cells to form α 2 β 1 -dependent adhesive interactions with bone matrices in vitro (26-28), we sought to determine whether our in vitro model accurately predicts α 2 integrin expression patterns found in type I collagen-rich metastatic lesions recovered from human breast cancer patients. For this, bone biopsy specimens were obtained from a series of seven patients with metastatic disease and immunostained for α 2 expression. Validating the results of our in vitro and xenograft models, all seven patients expressed α 2 in breast cancer cells in bone metastatic sites, with both carcinoma cells and surrounding vascular endothelial cells scoring positive in blinded analyses ( Fig. 5 and Fig. S5 ). Given that archived biopsy material was available from the original primary breast cancer site in a subset of three of these patients, and the fact that type I collagen levels are distinctly higher in human breast tissue than in mouse mammary gland (25), we assessed α 2 β 1 staining in these samples as well. Interestingly, distinct α 2 integrin expression was likewise detected in breast carcinoma cells in each of these patients (with weaker staining localized to normal myoepithelial cells), including tumor microemboli found within lymphatic vessels (Fig. S6) .
Discussion
Recent interest has focused on designing unbiased phenotypic screens wherein the identification of function-blocking effects precede efforts to dissect the underlying molecular mechanisms that give rise to the desired outcomes (13, 15, 31, 32) . With increasing evidence that cell behavior in 3D culture systems more faithfully recapitulates in vivo function, greater emphasis has been placed on developing improved in vitro models for screening purposes, including the use of basement membranelike gels, pepsin extracts of dermal collagen, and synthetic hydrogels (1, 2, 6, 33-35) . The degree to which any of these constructs recapitulate the structure or function of the native ECM deposited in vivo remains controversial, however (1, 2, 16, 34) . In carcinomatous states, neoplastic cells at both primary and metastatic sites are known to interface a network of covalently cross-linked type I collagen fibrils whose physical properties modulate tumor phenotypes (2, 3, (5) (6) (7) (8) (9) (10) (11) (12) 16) . Consequently, we elected to use type I collagen hydrogels that are naturally crosslinked by lysyl oxidase-derived aldimine bonds (16) to promote carcinoma cells to express a more in vivo-like display of surface antigens that could serve both as an immunogen for mAb production and as a physical platform for functional screening.
With this experimental approach, ∼5% of the generated cellreactive mAbs displayed inhibitory effects. mAb 4C3 was selected for additional analysis based on its inhibitory activity in our in vitro screen, and further characterized as a proof-ofprinciple prototype to determine (i) whether function-blocking activity detected initially in vitro can be extended into in vivo settings, (ii) whether the mAb-reactive antigen can be identified, and (iii) whether target antigens discovered using human carcinoma cell-type I collagen composites can faithfully predict in vivo patterns of expression in patient samples. As described above, mAb 4C3 successfully inhibited the perivascular proliferation of extravasated MDA-MB-231 cells within the type I collagen-rich interstitial matrix of the chicken embryo, a model xenograft system in which cancer cell behaviors, including invasion, proliferation, and metastasis, recapitulate those observed in mouse xenograft models (22, 23) .
We were initially surprised to find that mAb 4C3 did not affect primary tumor growth after orthotopic injection of MDA-MB-231 cells into the mouse mammary gland (Fig. S7) . However, assessment of the local ECM environment at the site of carcinoma inoculation confirmed earlier studies describing the paucity of type I collagen in the mouse mammary fat pad (25) . As an alternative, we chose mouse skeletal tissues as a surrogate tissue for assessing mAb 4C3-mediated effects on MDA-MB-231 proliferation, given its rich type I collagen content and the predilection of human breast carcinomas to metastasize to this organ system (17, (26) (27) (28) . Although the effects of mAb 4C3 on carcinoma growth within the mandible and hindlimb supported mAbmediated inhibitory effects, the high variability of this in vivo model did not allow these trends to reach statistical significance (Fig. 3) . More importantly, however, MDA-MB-231 proliferation in the vertebral column was almost completely inhibited, with significant effects on the development of paralysis-associated morbidity. Further studies are needed to assess the ability of mAb 4C3 to affect tumor growth within preestablished metastases, either as a single agent therapeutic or in combination with other interventions. Nevertheless, these findings provided sufficient impetus to warrant identification of the mAb 4C3 target antigen.
After immunoaffinity purification and mass spectroscopy, the mAb 4C3 target antigen was identified as the α 2 integrin subunit, whose only known partner, the β 1 integrin chain, forms a heterodimeric complex that serves as a major type I collagen-binding receptor (29, 30) . Peptide mapping characterized the mAb 4C3 epitope within the α-I domain of the α 2 integrin, a metal iondependent adhesion site that is responsible for ligand recognition and binding (29, 30) . Although these results complement a number of reports documenting important roles for α 2 β 1 in mediating cancer cell-type I collagen interactions in vitro, ranging from proliferation and invasion to epithelial-mesenchymal transition and cancer stem cell formation (36) (37) (38) (39) (40) (41) (42) (43) (44) (45) (46) (47) (48) , the function of the α 2 integrin in neoplastic states in the in vivo setting is less clear. Recently, Ramirez et al. (49) concluded that α 2 β 1 serves as a metastasis suppressor in mouse models as well as human cancers. Using α 2 integrin-null mice that were bred into a mouse mammary tumor virus-Neu transgenic line, they demonstrated that despite the complete absence of α 2 β 1 , tumor initiation was only marginally affected, whereas lung metastatic activity was actually enhanced (49) . In this mouse model, however, all tissues are rendered α 2 integrin-deficient throughout embryonic and postnatal development, and thus the MMTV-Neu oncogene is expressed, by necessity, in α 2 integrin-null mammary epithelial cells, where potential effects of the integrin on tumor transformation and progression are difficult to define (i.e., as opposed to deleting the α 2 integrin in committed carcinoma cells). Indeed, in contrast to these findings, targeting α 2 β 1 with either functionblocking antibodies or shRNA-based strategies has been reported to block metastatic activity in a number of animal model systems (50) (51) (52) (53) . Likewise, in a second in vivo model of cancer progression using α 2 -null mice bred into a K14-HPV16 transgenic line, squamous carcinoma cell proliferation and metastatic activities were decreased in the absence of the α 2 integrin (54) .
Independent of studies in mouse models, recent studies of human breast cancer and prostate cancer samples have indicated that α 2 mRNA expression levels can decrease as a function of increased metastatic burden and decreased survival (49) . However, at the protein level, α 2 β 1 is readily detected at both primary and metastatic sites in a variety of cancers, including breast (as described herein) and prostate cancer (52, 55, 56) . Although it may be reasonable to conclude that high levels of α 2 β 1 can potentially retard motile responses by promoting adhesion, lower levels of the integrin nevertheless may be required to support the cell-ECM interactions most conducive to invasion and growth.
Nevertheless, it is unlikely that all carcinomas will prove equally dependent on α 2 β 1 , considering that other collagen-binding adhesion molecules, including α 1 β 1, α 10 β 1, α 11 β 1 , and discoidin receptors, have been described previously (30) . As such, it should be stressed that the intent of using carcinoma cell-type I collagen composites as an antigen for mAb production is not to simply identify collagen-binding ligands, but rather to generate mAbs that interfere with cancer cell behavior in an environment similar to that encountered in vivo. Indeed, our preliminary studies indicate that most of the function-blocking mAbs identified in screens preformed to date target not type I collagen receptors, but rather surface molecules with as-yet uncharacterized mechanisms of action.
After applying the above-outlined strategy to identify function-blocking mouse antibodies, these reagents could be leveraged to generate humanized mAbs (14) . From a therapeutic perspective, the broad distribution of the α 2 β 1 integrin in normal tissues, as well as its ability to ligate other ECM proteins [e.g., type IV collagen, laminin, type XXIII collagen (30, 57) ], might raise concerns regarding potential toxicities associated with targeting strategies. However, it is noteworthy that α 2 -null mice are viable and fertile, and that α 2 -integrin-deficient human patients who present only with mild bleeding diatheses have been identified (58) (59) (60) (61) . Interestingly, small-molecule α 2 β 1 inhibitors have been developed as potential antithrombotic agents (62, 63) , but our preliminary studies indicate that these agents are not as effective as mAb 4C3, at least in terms of interfering with MDA-MB-231-type I collagen adhesive interactions (Fig. S8 ). Thus, it remains possible that mAb 4C3 exerts unique effects on carcinoma cell function that might not be recapitulated by smallmolecule inhibitors or α 2 integrin silencing. Finally, although our studies have emphasized potential roles for α 2 β 1 in neoplastic states, we note that the integrin also has been implicated in fibrosis, inflammation, platelet-mediated thrombosis, and angiogenesis, raising the possibility that similar targeting strategies might be applied in other diseases as well (64) (65) (66) (67) (68) (69) (70) .
The experimental approach outlined herein allows for the rapid identification of new target antigens in an unbiased fashion, as well as the isolation of murine mAbs suitable for humanization. Although our initial studies used a well-studied human breast carcinoma cell line, our approach is similarly amenable to the use of primary carcinoma cells or cancer stem cells. Indeed, we recently used primary human glioblastoma cancer stem cells to generate mAb libraries that were also found to exert inhibitory effects with target identification in process. As such, we anticipate that our phenotypic screening stratagem, using either human cancer cell lines, primary cancer cells, or even cancer cell-stromal cell composites (71) , as well as more complex ECM-supplemented hydrogels to better recapitulate the anticipated changes that occur in connective tissue composition during tumor progression (12, 72) , will prove valuable in the search for new targets and therapeutics in neoplastic states.
Methods
MDA-MB-231 cells (American Type Culture Collection) were embedded in mouse type I collagen hydrogels (21) . The cell-matrix composite was then inoculated into 6-wk-old BALB/c female mice for immunization. MDA-MB-231-reactive mAbs were isolated and screened for antiproliferative activity in 3D collagen constructs (21) . All procedures are described in more detail in SI Methods.
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SI Methods
Immunogen Preparation and Immunization. Type I collagen was isolated from mouse tail tendons as described previously (1) and dissolved in 0.2% acetic acid at a final concentration of 2.7 mg/mL Before gelation, the collagen solution was mixed with 10× minimum essential media (MEM) and 0.34 N NaOH at a ratio of 8:1:1 at 4°C, with MDA-MB-231 cells (1-5 × 10 6 ) suspended in 1 mL of this mixture. The carcinoma cell-collagen mixtures were incubated for 1 h at 37°C to allow for gelation and culture media (MEM supplemented with 10% FCS) added atop the gel. Collagen gel rigidity was assessed in a RFSII rheometer (Rheometrics) using dynamic shear mode, parallel plate geometry, and a hydrated chamber as described previously (2) .
After a 4-d incubation period, the MDA-MB-231/collagen composites were washed extensively and recovered intact from 12-well plates or, alternatively, after the MDA-MB-231 cells were harvested from the gels by dissolving the collagen hydrogels with collagenase type 3 (Advance BioFacture). MDA-MB-231/collagen composites or isolated MDA-MB-231 cells were inoculated i.p. into 6-wk-old BALB/c female mice, followed by boosts at 2-to 3-wk intervals for 3 mo. Spleens were then removed, and somatic cell hybridization was performed by the University of Michigan Hybridoma Core with P3 × 63-Ag8.653 mouse myeloma cells as the fusion partner (3).
Whole-Cell ELISA. Supernatants from hybridoma clones were assayed in a whole-cell ELISA format. MDA-MB-231 cells (1 × 10 5 ) were added to 96-well V-bottom PVC plates (Corning), and cell pellets were incubated for 1 h at 4°C with 50 μL of media supernatant from individual hybridoma cultures. After washing, MDA-MB-231 cells were then resuspended in PBS with an HRPconjugated secondary antibody directed against mouse immunoglobulins (Pierce) for 1 h at 4°C. The cells were then washed three times with PBS, and HRP activity was detected with a 3,3′,5,5′-tetramethylbenzidine substrate (Thermo Scientific).
Hybridomas giving rise to anti-MDA-MB-231-reactive mAbs were subcloned by limiting dilution and then reassayed for activity to ensure the isolation of monoclonal populations. Positive hybridomas were then used to generate ascites fluid by injection into mouse peritoneal cavities. The resulting ascites fluid was cleared of debris by centrifugation, and antibodies were purified using either Melon Gel Purification Resin or Protein G Resin (Thermo Scientific). mAb isotype was determined using the Rapid ELISA Mouse mAb Isotyping Kit (Pierce). A control IgG1 mAb (3H5) was raised against dengue virus antigen (4). After i.p. injection, ascites fluid generated from the hybridoma cell line [American Type Culture Collection (ATCC)] was purified by protein G affinity chromatography. Both the control mAb 3H5 and the mAb 4C3 preparations were endotoxin-depleted by DeToxi-Gel column chromatography (Pierce) before use.
Cell Proliferation and Apoptosis Assays. For screening mAb antiproliferative activity, MDA-MB-231 cells were embedded in type I collagen (10 5 cells in a final type I collagen concentration of 2.2 mg/mL) or Matrigel (5 mg/mL) in the absence or presence of mAb 4C3 at the indicated concentrations, and then plated in 24-well plates in MEM/10% FCS. In selected experiments, the ability of mAb 4C3 to affect the proliferative responses of human squamous cell carcinoma (74B), ovarian carcinoma (ES2), or fibrosarcoma (HT1080) cells (all obtained from ATCC) was assessed. Cell number was quantified by hemocytometry or by the Cell-Titer Glo Kit (Promega). Caspase 3 and caspase 7 activity was evaluated with the Caspase-Glo 3/7 Kit (Promega).
Affymetrix Expression Profiling and Analysis. Total mRNA was collected and purified using the RNeasy Mini Kit (Qiagen) (5). Sample quality was confirmed with a Bioanalyzer 2100 (Agilent), and all samples were profiled on Affymetrix Mouse MG-430 PM expression array strips. Expression values for each probe set were calculated using the robust multiarray average system (5) and filtered for genes with a fold change greater than twofold. Heat maps of selected gene lists were generated using Gene Cluster 3.0 and TreeView 1.6 (5). Gene Ontology analysis was performed using MetaCore from Thomson Reuters (version 6.11, build 41105).
Chick Xenograft. RFP-transduced MDA-MB-231 were injected with a control IgG or 4C3 into the allantoic vein of 11-d-old immune-incompetent chicken embryos (6) . After a 6-d incubation period, vessel lumens were visualized by injecting chicks with GFP-labeled isolectin-B4. Confocal imaging of second harmonic-generated signals was used to analyze collagen fiber microstructure as described previously (7) . After an additional 1 h of incubation time, embryos were harvested, whole-mount tissue preparations were obtained distal to the injection site, and carcinoma cells were identified by florescent microscopy. For quantification, MDA-MB-231 cells expressing firefly luciferase were injected in an identical fashion with control mAb 3H5 or mAb 4C3 in tandem with the carcinoma cells or at 24 h after the carcinoma cell inoculation. For imaging, eggs were injected i.v. with 100 μL of luciferin (40 mg/mL in PBS) at 10 min before removal of the lower chioroallantoic membrane. Membranes were washed with PBS and imaged for bioluminescence with a Xenogen IVIS 200 imaging system.
Mouse Xenograft Model. Luciferase-labeled MDA-MB-231 cells (1 × 10 5 ) were injected via the intracardiac route with either 10 mg/kg of mAb 4C3 or a control IgG1 twice weekly for 4 wk, and tumor progression was monitored by whole-body bioluminescent imaging as described previously (8) . In selected experiments, cells were alternatively injected orthotopically in the fourth mammary gland with or without mAb 4C3. Micro-CT analysis of bone lesions were imaged at an isotropic voxel resolution of 18 μm using Explore Locus SP (GE Healthcare), and calibrated 3D images were reconstructed (7).
Immunoaffinity Purification and Mass Spectrometry of Target
Antigen. To identify the mAb 4C3 ligand, RIPA lysates of MDA-MB-231 cells (1 mg/mL) were precleared with 5 μg of control mouse IgG1 and protein A/G beads (Santa Cruz Biotechnology). mAb 4C3 (5 μg) was then incubated with protein A/G beads overnight at 4°C. After the beads were pelleted and washed with RIPA buffer, attached proteins were solubilized in Laemmli sample buffer and resolved on 10% SDS/PAGE gels (Bio-Rad). The immunoprecipitated protein was visualized by silver staining (Pierce), with the band excised and subjected to in-gel digestion with porcine trypsin. Gel digests were analyzed by LC/MS/MS on a Thermo Scientific LTQ Orbitrap XL mass spectrometer. Peptide ion data were searched and identified using Mascot and Scaffold at the University of Michigan's Protein Structure Facility. To verify the indentified ligand, immunoprecipitated protein was resolved on SDS/PAGE gel, transferred to a nitrocellulose membrane, and immunoblotted with a second antibody against directed human integrin α2 (sc-74466; Santa Cruz Biotechnology).
Tissue Histochemistry. Formalin-fixed, paraffin-embedded tissue blocks from deidentified patient samples (Institutional Review Board protocol HUM000503390) were sectioned (5 μm) and placed on charged slides. The slides were the deparaffinized in xylene and rehydrated through graded alcohols. Heat-induced epitope retrieval was performed in a Decloaking Chamber (Biocare Medical) with Target Retrieval Solution at pH 6.0 (Dako). Slides were incubated in Peroxidazed (Biocare Medical) for 5 min to quench endogenous peroxidases, and then incubated for 1.5 h at 25°C with rabbit monoclonal anti-α2 integrin (CD49b; Abcam LTD/Epitomics) diluted 1:200. (This mAb produces superior staining than mAb 4C3.) Antibody was detected with anti-rabbit Envision + HRP-Labeled Polymer (Dako) for 30 min at 25°C. HRP staining was visualized with the DAB + Kit (Dako). Slides were counterstained in hematoxylin, blued in running tap water, dehydrated through graded alcohols, cleared in xylene, and then mounted with Permount (Fisher Scientific).
Statistical Analysis. All results are presented as the mean ± SEM of three or more experiments as indicated in the text. Significance was determined using the Student t test. Fig. S1 . MDA-MB-231 breast carcinoma cells, embedded in 3D type I collagen hydrogels (1) , are used to immunize recipient mice (2) . Hybridoma cultures are generated (3), and mAbs are tested for their ability to inhibt proliferative responses of MDA-MB-231 cells in 3D culture (4) . The ability of selected mAbs to inhibit MDA-MB-231 proliferative responses are determined in xenograft models in vivo (5) , and the antibody targets are identified by immunoaffinity isolation and mass spectroscopy (6) . ) were orthotopically injected into nude mouse recipients and either vehicle 250 μg mAb 4C3/mouse (∼10 mg/kg) or 500 μg mAb 4C3/mouse (∼20 mg/kg) given i.p. 3 times weekly, and tumor volume (A) and luminescence (B) were monitored as described. Results are expressed as mean ± SEM (n = 4). Fig. S8 . MDA-MB-231 cell adhesion to type I collagen hydrogels was assessed after a 1-h culture period with control IgG1 (10 μg/mL), mAb 4C3 (10 μg/mL), or the indicated concentrations of the small molecule α 2 β 1 antagonist, TC-I 15 (1) . Results are expressed as mean ± SEM (n = 3).
